title: Case of type 1 diabetes mellitus following interferon β-1a treatment for multiple sclerosis.
abstract: A 57-year-old woman who had been treated with interferon β-1a (IFNβ-1a) for multiple sclerosis was diagnosed with diabetic ketosis. Her fasting serum C-peptide (F-CPR) was 1.9 ng/mL and her daily urinary C-peptide (U-CPR) was 24.1 µg/day. Her anti-glutamic acid decarboxylase (GAD) antibody was 3.5 U/mL. Seven months later, she was hospitalized with body weight loss and a high level of hemoglobin A1c [11.1% (JDS)]. Her F-CPR and U-CPR were very low (0.1 ng/mL and 8.35 µg/day, respectively), and anti-GAD antibody became distinctly positive (12.4 U/mL). She had HLA-DRB1*04:05, A24, and B54. For these reasons, IFNβ-1a administration was considered a possible cause of type 1 diabetes mellitus in this case.
authors: Division of Diabetes and Endocrinology, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Japan. diabetesandendocrinology@gmail.com
authors: Taeko
authors: T
authors: Uonaga
authors: Kenichi
authors: K
authors: Yoshida
authors: Takanari
authors: T
authors: Harada
authors: Makiko
authors: M
authors: Shimodahira
authors: Yoshio
authors: Y
authors: Nakamura
mesh_terms: D001323:Autoantibodies / Q000097:blood; D002096:C-Peptide / Q000097:blood / Q000652:urine; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology* / Q000276:immunology / Q000378:metabolism; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006680:HLA Antigens; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
chemical_list: D001323:Autoantibodies; D002096:C-Peptide; D005968:Glutamate Decarboxylase; D006442:Glycated Hemoglobin; D006680:HLA Antigens; D000068556:Interferon beta-1a; D016899:Interferon-beta; C517652:hemoglobin A1c protein, human